Case Western Reserve researchers use AI with routine CT scans to predict how well lung cancer patients will respond to expensive treatment based off changes in texture patterns inside and outside the tumor.
Scientists from the Case Western Reserve University digital imaging lab, already pioneering the use of Artificial Intelligence (AI) to predict whether chemotherapy will be successful, can now determine which lung-cancer patients will benefit from expensive immunotherapy.
And, once again, they’re doing it by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy treatment. And, as with previous work, those changes have been discovered both inside—and outside—the tumor, a signature of the lab’s recent research.
“This is no flash in the pan—this research really seems to be reflecting something about the very biology of the disease, about which is the more aggressive phenotype, and that’s information oncologists do not currently have,” said Anant Madabhushi, whose Center for Computational Imaging and Personalized Diagnostics (CCIPD) has become a global leader in the detection, diagnosis and characterization of various cancers and other diseases by meshing medical imaging, machine learning and AI.
Currently, only about 20% of all cancer patients will actually benefit from immunotherapy, a treatment that differs from chemotherapy in that it uses drugs to help your immune system fight cancer, while chemotherapy uses drugs to directly kill cancer cells, according to the National Cancer Institute.
Madabhushi said the recent work by his lab would help oncologists know which patients would actually benefit from the therapy, and who would not.
“Even though immunotherapy has changed the entire ecosystem of cancer, it also remains extremely expensive—about $200,000 per patient, per year,” Madabhushi said. “That’s part of the financial toxicity that comes along with cancer and results in about 42% of all new diagnosed cancer patients losing their life savings within a year of diagnosis.”
Having a tool based on the research being done now by his lab would go a long way toward “doing a better job of matching up which patients will respond to immunotherapy instead of throwing $800,000 down the drain,” he added, referencing the four patients out of five who will not benefit, multiplied by annual estimated cost.
New research published
The new research, led by co-authors Mohammadhadi Khorrami and Prateek Prasanna, along with Madabhushi and 10 other collaborators from six different institutions (see list, below) was published this month in the journal Cancer Immunology Research.
Khorrami, a graduate student working at the CCIPD, said one of the more significant advances in the research was the ability of the computer program to note the changes in texture, volume and shape of a given lesion, not just its size.
“This is important because when a doctor decides based on CT images alone whether a patient has responded to therapy, it is often based on the size of the lesion,” Khorrami said. “We have found that textural change is a better predictor of whether the therapy is working.
“Sometimes, for example, the nodule may appear larger after therapy because of another reason, say a broken vessel inside the tumor—but the therapy is actually working. Now, we have a way of knowing that.”
Prasanna, a postdoctoral research associate in Madabhushi’s lab, said the study also showed that the results were consistent across scans of patients treated at two different sites and with three different types of immunotherapy agents.
“This is a demonstration of the fundamental value of the program, that our machine-learning model could predict response in patients treated with different immune checkpoint inhibitors,” he said. “We are dealing with a fundamental biological principal.”
Prasanna said the initial study used CT scans from 50 patients to train the computer and create a mathematical algorithm to identify the changes in the lesion. He said the next step will be to test the program on cases obtained from other sites and across different immunotherapy agents. This research recently won an ASCO 2019 Conquer Cancer Foundation Merit Award.
Additionally, Madabhushi said, researchers were able show that the patterns on the CT scans which were most associated with a positive response to treatment and with overall patient survival were also later found to be closely associated with the arrangement of immune cells on the original diagnostic biopsies of those patients.
This suggests that those CT scans actually appear to capturing the immune response elicited by the tumors against the invasion of the cancer—and that the ones with the strongest immune response were showing the most significant textural change and most importantly, would best respond to the immunotherapy, he said.
Madabhushi established the CCIPD at Case Western Reserve in 2012. The lab now includes nearly 60 researchers.
Some of the lab’s most recent work, in collaboration with New York University and Yale University, has used AI to predict which lung cancer patients would benefit from adjuvant chemotherapy based on tissue-slide images. That advancement was named by Prevention Magazine as one of the top 10 medical breakthroughs of 2018.
The Latest Google Headlines on:
The Latest Bing News on:
- Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology Industryon January 25, 2021 at 10:15 am
Immunotherapy using immune-checkpoint modulators has been revolutionizing the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the ...
- Notch Therapeutics Appoints Cellular Immunotherapy Veteran Chris Bond, Ph.D. as SVP, Preclinical and Translational Scienceson January 25, 2021 at 10:15 am
Notch Therapeutics Inc., a biotechnology company developing renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Chris Bond, Ph.D. as ...
- Allergy Immunotherapy Market will reach a valuation of US$ 2,892.2 Mn by the end of 2030on January 25, 2021 at 5:23 am
Allergy Immunotherapy Market Players Promoting Novel Treatment Options to Reduce Reluctance – Future market Insights. Demand for allergy immunotherapy to ...
- Cancer Immunotherapy Market – Detailed Analysis of Current Industry Figures with Forecasts Growth By 2026on January 24, 2021 at 11:42 pm
Selbyville, Delaware According to the recent research report titled 'Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report By Type; By Application; By End-user; By Regions, ...
- What Is Immunotherapy? The Next Wave in Cancer Treatment, Explainedon January 24, 2021 at 7:46 am
For decades, the most effective treatments for cancer have involved surgery and rounds of chemotherapy or radiation. But some of those treatments can harm healthy cells, which is why advancements that ...
- Global Cellular Immunotherapy Market Report 2020-2030 - ResearchAndMarkets.comon January 23, 2021 at 12:14 am
COVID-19 Growth and Change” report has been added to ResearchAndMarkets.com’s offering. Cellular Immunotherapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, ...
- F-star Therapeutics: New Biologics Platform For Immunotherapyon January 21, 2021 at 8:00 am
Potential to close larger developmental deals from its platform and pipeline and the blockbuster potential of these drug candidates, make F-star a compelling long-term investment. F-star Therapeutics ...
- Immunotherapy biotech NexImmune files for an $86 million IPOon January 19, 2021 at 1:42 pm
N exImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. NexImmune is developing a novel ...
- Study predicts good passive immunotherapy donors to combat COVID-19on January 19, 2021 at 10:09 am
A US-based research team determine good candidates for convalescent plasma donations in promoting passive immunity among severely-ill COVID-19 patients.
- Unexpectedly, Immunotherapy Response Linked to Low TMB in rGMBon January 19, 2021 at 8:55 am
In contrast to what has been seen in other tumor types, recurrent glioblastoma (rGMB) appears to respond better to immunotherapy when tumor mutational burden (TMB) is low.
The Latest Google Headlines on:
Artificial intelligence diagnostics
The Latest Bing News on:
Artificial intelligence diagnostics
- How artificial intelligence will transform the future of dentistryon January 25, 2021 at 10:12 am
The COVID-19 pandemic has disrupted life in all kinds of ways, which has caused damage in a myriad of areas – including our oral health. The past year has ...
- Prostate Cancer may be diagnosed using a urine test with artificial intelligenceon January 25, 2021 at 7:45 am
Prostate cancer is one of the most common cancers among men. Patients are determined to have prostate cancer primarily based on *PSA, a cancer factor in blood. However, as diagnostic accuracy is ...
- Healthcare Artificial Intelligence Market Trends Global Industry Analysis, Top Manufacturers, Growth, Opportunities & Forecast to 2026on January 25, 2021 at 6:37 am
Jan (Market Insight Reports) -- Selbyville, Delaware, Market Study Report LLC recently added a new title on 2020-2026 Global Healthcare ...
- UAE-Based Prognica Labs Uses Artificial Intelligence To Detect Masses In Mammography Screeningson January 23, 2021 at 7:42 pm
The healthtech startup aims to achieve its mission of further improving the quality of diagnostic standards, and improve its machine learning capabilities for greater accuracy for early detection of ...
- Aiforia partners with Pathan to bring artificial intelligence assisted diagnostics to the pathology labon January 21, 2021 at 6:30 am
Pathan, one of the largest pathology laboratories in the Netherlands, has started a collaboration with Aiforia, a leading software ...
- Kahun Launches AI Diagnostic Tool for Frontline Doctorson January 21, 2021 at 3:13 am
Kahun, an Israeli medtech startup that utilizes artificial intelligence (AI), has announced the beta release of its diagnostic app for medical professionals. The application has already been widely ...
- Healthcare Artificial Intelligence (AI) Market Worth $51.3 Billion by 2027 at a CAGR of 41.4%on January 20, 2021 at 6:07 am
According to this latest publication from Meticulous Research(R), the healthcare artificial intelligence market is ...
- Caris Life Sciences Accurately Identifies 21 Cancer Types Using Artificial Intelligence Derived Molecular Signatureson January 19, 2021 at 10:24 pm
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, today announced positive results from a study using ...
- Scientists develop an artificial intelligence system for analyzing endoscopic imageson January 19, 2021 at 3:44 pm
Researchers of Peter the Great St.Petersburg Polytechnic University, in collaboration with the Almazov National Medical Research Centre, developed an artificial intelligence system for analyzing ...
- Global Healthcare Artificial Intelligence Market, 2020-2027 - Growing Incorporation of AI in Clinical Trials to Accelerate New Drug Launcheson January 19, 2021 at 11:19 am
The "Healthcare Artificial Intelligence Market - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The global healthcare artificial intelligence (AI) market is ...